Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Novavax Inc (NASDAQ:NVAX)

During the Trading Day
8.04 +0.43 / +5.65%
As of 3:59pm ET
Day’s Change
During After-Hours   Switch to standard view »
8.04 +0.0016 / +0.02%
Volume: 30.1K
Health Technology

Company Description

Novavax, Inc. operates as a clinical-stage biopharmaceutical company, which engages in development of novel recombinant vaccines to address a broad range of infectious diseases. The company's technology platform is based on proprietary recombinant vaccine technology that includes virus-like particles and recombinant nanoparticle vaccines. Its product pipeline targets a variety of infectious diseases and currently has completed clinical trials that target pandemic influenza (H5N1), seasonal influenza and Respiratory Syncytial Virus. Novavax was founded in 1987 and is headquartered in Gaithersburg, MD.

Contact Information

Novavax, Inc.
20 Firstfield Road
Gaithersburg Maryland 20878
P:(240) 268-2000
Investor Relations:



Individual stakeholders7.29%
Mutual fund holders49.08%
Other institutional19.24%

Top Executives

Stanley C. ErckPresident, Chief Executive Officer & Director
Barclay A. PhillipsChief Financial Officer, Treasurer & Senior VP
Gregory M. GlennSenior Vice President-Research & Development
Louis F. FriesChief Medical Officer & Vice President
John A. HerrmannSecretary, Senior Vice President & General Counsel